Advaxis, Inc. announced that it has appointed Fred J. Frullo as vice president, regulatory affairs. With more than 20 years of experience in the biopharmaceutical industry, Frullo is well versed in the development of global regulatory strategies for the supervision, review and assembly of pharmaceutical product submission and coordination with global health authorities to obtain approvals. As vice president, regulatory affairs, Frullo will oversee regulatory submissions for the company's Lm-LLO cancer immunotherapy clinical programs, including ADXS-HPV, ADXS-PSA and ADXS-HER2, as well as combination studies involving complementary immunotherapy technologies.

Frullo will lead the development and submission of all regulatory documents on behalf of Advaxis to the appropriate health agencies and coordinating joint submissions with Advaxis's strategic partners as warranted. In this role, Frullo will succeed Chris L. French, who will now lead the company's compliance program. Frullo was previously the director, global regulatory strategy at Bristol-Myers Squibb, where he was responsible for maintaining regulatory compliance for the oncology portfolio of marketed products and providing global regulatory strategy support for both Life Cycle Management Teams and Early Development Teams.